DIGITAL EVENT
Wednesday, June 8, 2022 | 8.55 AM - 3.30 PM (EST)
8:55 am Chair’s Opening Remarks
8:55 am Chair’s Opening Remarks
9:00 am 2022 & Beyond: What’s the Current & Future State of the JAK Inhibitor Landscape
9:00 am 2022 & Beyond: What’s the Current & Future State of the JAK Inhibitor Landscape
Synopsis
- Outlining the successes of the past year in JAK inhibitor drug development
- Reflecting on the JAK black box warning and the implications this may have on
the industry moving forward - Highlighting the hot-pockets of innovation where we can expect JAK inhibitors
to excel
Reviewing JAK Inhibitor Formulation & Drug Delivery Systems
Reviewing JAK Inhibitor Formulation & Drug Delivery Systems
9:30 am PANEL DISCUSSION – The Road Ahead: Topicals vs Orals vs Alternative Delivery Methods
9:30 am PANEL DISCUSSION – The Road Ahead: Topicals vs Orals vs Alternative Delivery Methods
Synopsis
- Exploring the JAK inhibitor drug development landscape and weighing the merit of pursuing topical vs oral vs
alternative application - Considering the cost concerns and systemic effects associated with oral and injectable delivery systems whilst
discussing the small potential for off-target effects in topical creams - Discussing the need to equate disease severity and quality of life with safety concerns associated with JAK inhibition
- Reflecting on the practicality of topical delivery as a long-term disease management strategy
10:15 am The Story of Ruxolitinib: The First Approved Topical JAK Inhibitor for Atopic Dermatitis
10:15 am The Story of Ruxolitinib: The First Approved Topical JAK Inhibitor for Atopic Dermatitis
Synopsis
- The story from discovery to clinical development for a moderate to severe
inflammatory skin indication - Inspecting the JAK/STAT pathways critical to Incyte’s JAK inhibitor portfolio
- Reviewing the commercialization and market strategy of a ‘twice daily’ applied
topical cream
10:45 am
Morning Break & Speed Networking Session
10:45 am
Morning Break & Speed Networking Session
11:15 am Overview of JAK Inhibitor Inhaled Formulation
11:15 am Overview of JAK Inhibitor Inhaled Formulation
Synopsis
- Cataloguing autoimmune diseases where JAK inhalation may be sensible
- Considering toxicity and potential for off-target effects with inhaled JAKs
- Evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of
a novel potent pan-JAK inhaled as a dry powder
11:45 am Repositioning a JAKi to Reduce Mortality in Patients with COVID-19
11:45 am Repositioning a JAKi to Reduce Mortality in Patients with COVID-19
Synopsis
- Rationalizing the use of a JAKi in COVID-19 patients
- Reviewing the data from a phase 3 COVID-19 trial
- Exploring other potential novel therapeutic targets for Baricitinib
12:15 pm
Lunch Break
12:15 pm
Lunch Break
Weighing the Benefit-Risk: Reviewing How We Measure Safety Against Practicality
Weighing the Benefit-Risk: Reviewing How We Measure Safety Against Practicality
1:15 pm Exploring the Potential for JAK1 Selectivity in Autoimmune Dermatological Conditions
1:15 pm Exploring the Potential for JAK1 Selectivity in Autoimmune Dermatological Conditions
Synopsis
- Overcoming pre-clinical hurdles in dermatology to enable topical JAK inhibitor development
- Considering route of delivery and the implications on safety and efficacy
- Preparing a JAK inhibitor pipeline for transition from pre-clinic to phase 1 trials
1:45 pm Shedding Light on the Patient Perspective in the Clinic
1:45 pm Shedding Light on the Patient Perspective in the Clinic
Synopsis
- Unearthing unique considerations for JAK inhibitor use in pediatrics
- Comparing and contrasting the deployment of JAK inhibitors in rheumatology vs dermatology
- Moving forward: what conditions stand to benefit most from JAK inhibitor
development